



State of New Jersey

DEPARTMENT OF HEALTH

DIVISION OF EPIDEMIOLOGY, ENVIRONMENTAL AND OCCUPATIONAL HEALTH

PO BOX 369

TRENTON, N.J. 08625-0369

CHRIS CHRISTIE  
Governor

[www.nj.gov/health](http://www.nj.gov/health)

KIM GUADAGNO  
Lt. Governor

CATHLEEN D. BENNETT  
Acting Commissioner

November 30, 2015

Dear Healthcare Provider:

The Centers for Disease Control and Prevention (CDC) has informed the New Jersey Department of Health (NJDOH), Vaccine Preventable Disease Program (VPDP) of a Pentacel® (DTaP-IPV/HiB) vaccine manufacturing delay. Sanofi-Pasteur is communicating directly with healthcare providers with information about the Pentacel® delay via a Healthcare Provider Letter. This delay affects both private and public vaccine supplies.

To ensure that there is equitable access to Sanofi-Pasteur's pertussis-containing vaccines and related products, CDC will be allocating the following vaccines to the Vaccines for Children (VFC) Programs: Pentacel®, DAPTACEL® (DTaP), IPOL® (IPV), and ActHIB® (HiB).

The New Jersey VFC Program asks that you conduct an inventory of your vaccine stock to ensure that you order appropriate vaccines to meet the needs of your patient population. Please be aware that the VFC Program staff might need to reduce the number of doses of the impacted vaccines shipped during this time.

At this time, since there are ample supplies of alternative products, the vaccine requirements stipulated in 8:57-4, *Immunization of Pupils in School*, remain in effect.

We will continue to monitor the situation over the coming months and will provide updates as necessary. Please do not hesitate to contact us with any questions or concerns at 609-826-4861.

Sincerely,

Barbara Montana, MD, MPH, FACP  
Medical Director  
Communicable Disease Service